Genetics/Genomics News

Therapeutic and genetic antagonism of angiopoietin-like 3 decreased lipid levels and the risk for atherosclerotic CVD, according to a study in The New England Journal of Medicine.

PHILADELPHIA — Genomics, proteomics and imaging may enable a personalized medicine strategy for patients with familial hypercholesterolemia, an expert said at the National Lipid Association Scientific Sessions.

PHILADELPHIA — In patients with low HDL, a damaging mutation in ABCA1 or APOA1 is associated with an increased risk for subclinical atherosclerosis compared with patients without a mutation, according to a poster presentation at the National Lipid Association Scientific Sessions.

Patients with symptoms of obstructive CAD with a low score using a blood-based age/sex/gene expression test were less likely to be referred to a cardiologist, have positive findings and have an adverse CV event after 1 year, according to a study in The American Journal of Medicine.

Individuals with a deficiency of angiopoietin-like 3 had a decreased risk for CAD, even in the presence of risk factors, according to findings in the Journal of the American College of Cardiology.

The American College of Cardiology Scientific Session featured important late- break ing clinical trials and other material presented by some of the world’s leading cardiologists. Cardiology Today has compiled a list of the top studies, presentations and abstracts presented at the meeting this year.

Researchers have determined a cause for severe hypertriglyceridemia and chylomicronemia.

WASHINGTON — Pharmacogenetics-based warfarin dosing decreased adverse events compared with clinical-based dosing, investigators from the GIFT study reported at the American College of Cardiology Scientific Session.

WASHINGTON — Inclisiran, a small interfering RNA that targets PCSK9 messenger RNA, was associated with reduced LDL and PCSK9 in the phase 2 ORION-1 study.

CVD is the leading cause of death in the United States, with about 610,000 related deaths each year, according to the CDC. Genetics play an important role in determining who is most at risk for CVD. However, long-held assumptions about genetic CV risk have proven not to be true, and many cardiologists are beginning to take a more active role in managing risk for these patients.